Pfizer says three-dose regimen of pediatric vaccine effective for ages 6 months to under 5

Pfizer announced on Monday that a third pediatric dose of its vaccine against the coronavirus in children ages 6 months to under five years old provides a strong immune response and is safe. The company cited its clinical trials, in which the pediatric dose – which is one-tenth of the dose given to adults – showed an efficacy of 80.3% in preliminary analyses. Pfizer said it would submit the new data to the US Food and Drug Administration in a bid to get the FDA’s approval for a three-shot regimen of the pediatric dose for the young age group.